Overall neutralization of complement factor H by autoantibodies in the acute phase of the autoimmune form of atypical hemolytic uremic syndrome

Journal of Immunology

Volumn 189, Issue 7, 2012, Pages 3528-3537

  Blanc, Caroline ^a,b   Roumenina, Lubka T ^a   Ashraf, Yahya ^a   Hyvärinen, Satu ^c   Sethi, Sidharth Kumar ^d   Ranchin, Bruno ^e   Niaudet, Patrick ^f   Loirat, Chantal ^g   Gulati, Ashima ^d   Bagga, Arvind ^d   Fridman, Wolf Herman ^a,b,h   Sautès Fridman, Catherine ^a,b   Jokiranta, T Sakari ^c   Frémeaux Bacchi, Véronique ^a,h   Dragon Durey, Marie Agnes̀ ^a,b,h  

^a CENTRE DE RECHERCHE DES CORDELIERS   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c UNIVERSITY OF HELSINKI   (Finland)

^d ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^e HOSPICES CIVILS DE LYON   (France)

^f HÔPITAL NECKER ENFANTS MALADES   (France)

^g HÔPITAL ROBERT DEBRÉ   (France)

^h HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C3C; COMPLEMENT COMPONENT C3D; COMPLEMENT COMPONENT C5; COMPLEMENT FACTOR H; COMPLEMENT FACTOR H ANTIBODY; COMPLEMENT FACTOR H RELATED 1 PROTEIN; COMPLEMENT FACTOR H RELATED 2 PROTEIN; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G3 ANTIBODY; UNCLASSIFIED DRUG;

ADULT; ANTIBODY TITER; ANTIGEN ANTIBODY COMPLEX; ANTIGEN BINDING; ARTICLE; CELL PROTECTION; CFHR1 GENE; CFHR3 GENE; CHILD; CLINICAL ARTICLE; COMPLEMENT BLOOD LEVEL; CONTROLLED STUDY; DISEASE SEVERITY; EPITOPE MAPPING; GENE DELETION; GENETIC ANALYSIS; HEMOLYTIC UREMIC SYNDROME; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; PRIORITY JOURNAL;

ACUTE DISEASE; ADULT; AUTOANTIBODIES; AUTOIMMUNE DISEASES; CHILD; COMPLEMENT C3; COMPLEMENT FACTOR H; HEMOLYTIC-UREMIC SYNDROME; HUMANS; NEUTRALIZATION TESTS; PROTEIN BINDING;

EID: 84866556872     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1200679     Document Type: Article

References (32)

1. Ricklin, D., G. Hajishengallis, K. Yang, and J. D. Lambris. 2010. Complement: a key system for immune surveillance and homeostasis. Nat. Immunol. 11: 785-797.
2. Noris, M., and G. Remuzzi. 2009. Atypical hemolytic-uremic syndrome. N. Engl. J. Med. 361: 1676-1687.
3. Dragon-Durey, M. A., and V. Frémeaux-Bacchi. 2005. Atypical haemolytic uraemic syndrome and mutations in complement regulator genes. Springer Semin. Immunopathol. 27: 359-374. (Pubitemid 41639887)
4. Roumenina, L. T., C. Loirat, M.-A. Dragon-Durey, L. Halbwachs-Mecarelli, C. Sautes-Fridman, and V. Fremeaux-Bacchi. 2011. Alternative complement pathway assessment in patients with atypical HUS. J. Immunol. Methods 365: 8-26.
5. Dragon-Durey, M. A., C. Loirat, S. Cloarec, M. A. Macher, J. Blouin, H. Nivet, L. Weiss, W. H. Fridman, and V. Frémeaux-Bacchi. 2005. Anti-factor H autoantibodies associated with atypical hemolytic uremic syndrome. J. Am. Soc. Nephrol. 16: 555-563. (Pubitemid 41725154)
6. Dragon-Durey, M.-A., S. K. Sethi, A. Bagga, C. Blanc, J. Blouin, B. Ranchin, J.-L. André, N. Takagi, H. I. Cheong, P. Hari, et al. 2010. Clinical features of antifactor H autoantibody-associated hemolytic uremic syndrome. J. Am. Soc. Nephrol. 21: 2180-2187.
7. Rodríguez de Córdoba, S., J. Esparza-Gordillo, E. Goicoechea de Jorge, M. Lopez-Trascasa, and P. Sánchez-Corral. 2004. The human complement factor H: functional roles, genetic variations and disease associations. Mol. Immunol. 41: 355-367. (Pubitemid 38639887)
8. Schmidt, C. Q., A. P. Herbert, D. Kavanagh, C. Gandy, C. J. Fenton, B. S. Blaum, M. Lyon, D. Uhrín, and P. N. Barlow. 2008. A new map of glycosaminoglycan and C3b binding sites on factor H. J. Immunol. 181: 2610-2619.
9. Bhattacharjee, A., M. J. Lehtinen, T. Kajander, A. Goldman, and T. S. Jokiranta. 2010. Both domain 19 and domain 20 of factor H are involved in binding to complement C3b and C3d. Mol. Immunol. 47: 1686-1691.
10. Kajander, T., M. J. Lehtinen, S. Hyvärinen, A. Bhattacharjee, E. Leung, D. E. Isenman, S. Meri, A. Goldman, and T. S. Jokiranta. 2011. Dual interaction of factor H with C3d and glycosaminoglycans in host-nonhost discrimination by complement. Proc. Natl. Acad. Sci. USA 108: 2897-2902.
11. Morgan, H. P., C. Q. Schmidt, M. Guariento, B. S. Blaum, D. Gillespie, A. P. Herbert, D. Kavanagh, H. D. T. Mertens, D. I. Svergun, C. M. Johansson, et al. 2011. Structural basis for engagement by complement factor H of C3b on a self surface. Nat. Struct. Mol. Biol. 18: 463-470.
12. Józsi, M., C. Licht, S. Strobel, S. L. Zipfel, H. Richter, S. Heinen, P. F. Zipfel, and C. Skerka. 2008. Factor H autoantibodies in atypical hemolytic uremic syndrome correlate with CFHR1/CFHR3 deficiency. Blood 111: 1512-1514. (Pubitemid 351213440)
13. Moore, I., L. Strain, I. Pappworth, D. Kavanagh, P. N. Barlow, A. P. Herbert, C. Q. Schmidt, S. J. Staniforth, L. V. Holmes, R. Ward, et al. 2010. Association of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4, and with mutations in CFH, CFI, CD46, and C3 in patients with atypical hemolytic uremic syndrome. Blood 115: 379-387.
14. Dragon-Durey, M. A., C. Blanc, F. Marliot, C. Loirat, J. Blouin, C. Sautes-Fridman, W. H. Fridman, and V. Frémeaux-Bacchi. 2009. The high frequency of complement factor H related CFHR1 gene deletion is restricted to specific subgroups of patients with atypical haemolytic uraemic syndrome. J. Med. Genet. 46: 447-450.
15. Heinen, S., A. Hartmann, N. Lauer, U. Wiehl, H.-M. Dahse, S. Schirmer, K. Gropp, T. Enghardt, R. Wallich, S. Hälbich, et al. 2009. Factor H-related protein 1 (CFHR-1) inhibits complement C5 convertase activity and terminal complex formation. Blood 114: 2439-2447.
16. Eberhardt, H. E., Q. Chen, P. Zipfel, and C. Skerka. 2011. Human complement factor H-related protein 2 (CFHR2) represents a novel complement regulator, which is reduced in a patient with MPGN I. Mol. Immunol. 48: 1674.
17. Zipfel, P. F., M. Edey, S. Heinen, M. Józsi, H. Richter, J. Misselwitz, B. Hoppe, D. Routledge, L. Strain, A. E. Hughes, et al. 2007. Deletion of complement factor H-related genes CFHR1 and CFHR3 is associated with atypical hemolytic uremic syndrome. PLoS Genet. 3: e41.
18. Józsi, M., S. Strobel, H.-M. Dahse, W. S. Liu, P. F. Hoyer, M. Oppermann, C. Skerka, and P. F. Zipfel. 2007. Anti factor H autoantibodies block C-terminal recognition function of factor H in hemolytic uremic syndrome. Blood 110: 1516-1518. (Pubitemid 47443967)
19. Strobel, S., P. F. Hoyer, C. J. Mache, E. Sulyok, W. S. Liu, H. Richter, M. Oppermann, P. F. Zipfel, and M. Józsi. 2010. Functional analyses indicate a pathogenic role of factor H autoantibodies in atypical haemolytic uraemic syndrome. Nephrol. Dial. Transplant. 25: 136-144.
20. Strobel, S., C. Abarrategui-Garrido, E. Fariza-Requejo, H. Seeberger, P. Sánchez-Corral, and M. Józsi. 2011. Factor H-related protein 1 neutralizes anti-factor H autoantibodies in autoimmune hemolytic uremic syndrome. Kidney Int. 80: 397-404.
21. Sánchez-Corral, P., C. González-Rubio, S. Rodríguez de Córdoba, and M. López-Trascasa. 2004. Functional analysis in serum from atypical hemolytic uremic syndrome patients reveals impaired protection of host cells associated with mutations in factor H. Mol. Immunol. 41: 81-84. (Pubitemid 38609399)
22. Jokiranta, T. S., V.-P. Jaakola, M. J. Lehtinen, M. Pärepalo, S. Meri, and A. Goldman. 2006. Structure of complement factor H carboxyl-terminus reveals molecular basis of atypical haemolytic uremic syndrome. EMBO J. 25: 1784-1794.
23. Pechtl, I. C., D. Kavanagh, N. McIntosh, C. L. Harris, and P. N. Barlow. 2011. Disease-associated N-terminal complement factor H mutations perturb cofactor and decay-accelerating activities. J. Biol. Chem. 286: 11082-11090.
24. Saunders, R. E., C. Abarrategui-Garrido, V. Frémeaux-Bacchi, E. Goicoechea de Jorge, T. H. J. Goodship, M. López Trascasa, M. Noris, I. M. Ponce Castro, G. Remuzzi, S. Rodríguez de Córdoba, et al. 2007. The interactive factor Hatypical hemolytic uremic syndrome mutation database and website: update and integration of membrane cofactor protein and factor I mutations with structural models. Hum. Mutat. 28: 222-234.
25. Józsi, M., S. Heinen, A. Hartmann, C. W. Ostrowicz, S. Hälbich, H. Richter, A. Kunert, C. Licht, R. E. Saunders, S. J. Perkins, et al. 2006. Factor H and atypical hemolytic uremic syndrome: mutations in the C-terminus cause structural changes and defective recognition functions. J. Am. Soc. Nephrol. 17: 170-177.
26. Jokiranta, T. S., J. Hellwage, V. Koistinen, P. F. Zipfel, and S. Meri. 2000. Each of the three binding sites on complement factor H interacts with a distinct site on C3b. J. Biol. Chem. 275: 27657-27662.
27. Henderson, A. L., M. A. Lindorfer, A. D. Kennedy, P. L. Foley, and R. P. Taylor. 2002. Concerted clearance of immune complexes bound to the human erythrocyte complement receptor: development of a heterologous mouse model. J. Immunol. Methods 270: 183-197.
28. Kavai, M., and G. Szegedi. 2007. Immune complex clearance by monocytes and macrophages in systemic lupus erythematosus. Autoimmun. Rev. 6: 497-502. (Pubitemid 47069975)
29. Kavai, M. 2008. Immune complex clearance by complement receptor type 1 in SLE. Autoimmun. Rev. 8: 160-164.
30. Scully, M. 2010. Inhibitory anti-ADAMTS 13 antibodies: measurement and clinical application. Blood Rev. 24: 11-16.
31. Franchini, M., and G. Lippi. 2011. Acquired hemophilia A. Adv. Clin. Chem. 54: 71-80.
32. Dragon-Durey, M.-A., C. Blanc, A. Garnier, J. Hofer, S. K. Sethi, and L. B. Zimmerhackl. 2010. Anti-factor H autoantibody-associated hemolytic uremic syndrome: review of literature of the autoimmune form of HUS. Semin. Thromb. Hemost. 36: 633-640.